{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:57:43Z","timestamp":1791899863341,"version":"4.3.4"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":700,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>Increased production of vasoconstrictive prostanoids, such as thromboxane A2 (TXA2), contributes to endothelial dysfunction and increased hepatic vascular tone in cirrhosis. TXA2 induces vasoconstriction by way of activation of the thromboxane-A2\/prostaglandin-endoperoxide (TP) receptor. This study investigated whether terutroban, a specific TP receptor blocker, decreases hepatic vascular tone and portal pressure in rats with cirrhosis due to carbon tetrachloride (CCl4) or bile duct ligation (BDL). Hepatic and systemic hemodynamics, endothelial dysfunction, liver fibrosis, hepatic Rho-kinase activity (a marker of hepatic stellate cell contraction), and the endothelial nitric oxide synthase (eNOS) signaling pathway were measured in CCl4 and BDL cirrhotic rats treated with terutroban (30 mg\/kg\/day) or its vehicle for 2 weeks. Terutroban reduced portal pressure in both models without producing significant changes in portal blood flow, suggesting a reduction in hepatic vascular resistance. Terutroban did not significantly change arterial pressure in CCl4-cirrhotic rats but decreased it significantly in BDL-cirrhotic rats. In livers from CCl4 and BDL-cirrhotic terutroban-treated rats, endothelial dysfunction was improved and Rho-kinase activity was significantly reduced. In CCl4-cirrhotic rats, terutroban reduced liver fibrosis and decreased alpha smooth muscle actin (\u03b1-SMA), collagen-I, and transforming growth factor beta messenger RNA (mRNA) expression without significant changes in the eNOS pathway. In contrast, no change in liver fibrosis was observed in BDL-cirrhotic rats but an increase in the eNOS pathway.<\/jats:bold>\n                                 <jats:bold>\n                                    Conclusion\n                                 <\/jats:bold>\n                                 <jats:bold>: Our data indicate that TP-receptor blockade with terutroban decreases portal pressure in cirrhosis. This effect is due to decreased hepatic resistance, which in CCl4-cirrhotic rats was linked to decreased hepatic fibrosis, but not in BDL rats, in which the main mediator appeared to be an enhanced eNOS-dependent vasodilatation, which was not liver-selective, as it was associated with decreased arterial pressure. The potential use of terutroban for portal hypertension requires further investigation. (Hepatology 2013;58:1424\u20131435)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.26520","type":"journal-article","created":{"date-parts":[[2013,5,23]],"date-time":"2013-05-23T21:31:05Z","timestamp":1369344665000},"page":"1424-1435","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":41,"title":["Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats"],"prefix":"10.1097","volume":"58","author":[{"given":"Eugenio","family":"Rosado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aina","family":"Rodr\u00edguez-Vilarrupla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Gracia-Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9ctor","family":"Garc\u00eda-Calder\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Garc\u00eda-Pag\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-28-20241201","doi-asserted-by":"crossref","first-page":"141156","DOI":"10.1016\/S0168-8278(00)80422-5","article-title":"Complications of cirrhosis. I. Portal hypertension.","volume":"32","author":"Bosch","year":"2000","journal-title":"J Hepatol"},{"key":"R2-28-20241201","doi-asserted-by":"crossref","first-page":"S125S130","DOI":"10.1097\/01.mcg.0000155552.14396.3d","article-title":"Portal hypertension: from bedside to bench.","volume":"39","author":"Groszmann","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"R3-28-20241201","doi-asserted-by":"crossref","first-page":"172181","DOI":"10.1053\/jhep.2003.50004","article-title":"Cyclooxygenasederived products modulate the increased intrahepatic resistance of cirrhotic rat livers.","volume":"37","author":"Graupera","year":"2003","journal-title":"Hepatology"},{"key":"R4-28-20241201","doi-asserted-by":"crossref","first-page":"515521","DOI":"10.1016\/S0168-8278(03)00347-7","article-title":"Cyclooxygenase1 inhibition corrects endothelial dysfunction in cirrhotic rat livers.","volume":"39","author":"Graupera","year":"2003","journal-title":"J Hepatol"},{"key":"R5-28-20241201","doi-asserted-by":"crossref","first-page":"478491","DOI":"10.1053\/jhep.2002.31432","article-title":"The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough.","volume":"35","author":"Wiest","year":"2002","journal-title":"Hepatology"},{"key":"R6-28-20241201","first-page":"G567G574","article-title":"Deficit in nitric oxide production in cirrhotic rat livers is located in the sinusoidal and postsinusoidal areas.","volume":"284","author":"LoureiroSilva","year":"2003","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R7-28-20241201","doi-asserted-by":"crossref","first-page":"G763G770","DOI":"10.1152\/ajpgi.00300.2004","article-title":"Sinusoidal endothelial COX1derived prostanoids modulate the hepatic vascular tone of cirrhotic rat livers.","volume":"288","author":"Graupera","year":"2005","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R8-28-20241201","doi-asserted-by":"crossref","first-page":"24612470","DOI":"10.1111\/j.1582-4934.2012.01563.x","article-title":"Interaction between NO and COX pathways modulating hepatic endothelial cells from control and cirrhotic rats.","volume":"16","author":"Rosado","year":"2012","journal-title":"J Cell Mol Med"},{"key":"R9-28-20241201","first-page":"220227","article-title":"Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers.","volume":"47","author":"GraciaSancho","year":"2007","journal-title":"J Hepatol"},{"key":"R10-28-20241201","doi-asserted-by":"crossref","first-page":"903923","DOI":"10.2174\/138161206776055921","article-title":"From the design to the clinical application of thromboxane modulators.","volume":"12","author":"Dogne","year":"2006","journal-title":"Curr Pharm Des"},{"key":"R11-28-20241201","doi-asserted-by":"crossref","first-page":"124131","DOI":"10.1038\/labinvest.3700712","article-title":"F2isoprostane receptors on hepatic stellate cells.","volume":"88","author":"Gardi","year":"2008","journal-title":"Lab Invest"},{"key":"R12-28-20241201","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.pharmthera.2008.01.001","article-title":"Thromboxane A2: physiologypathophysiology, cellular signal transduction and pharmacology.","volume":"118","author":"Nakahata","year":"2008","journal-title":"Pharmacol Ther"},{"key":"R13-28-20241201","first-page":"13811386","article-title":"New tetrahydronaphthalene derivatives as combined thromboxane receptor antagonists and thromboxane synthase inhibitors.","volume":"8","author":"Cimetiere","year":"1998","journal-title":"Bioorg Med Chem Lett"},{"key":"R14-28-20241201","doi-asserted-by":"crossref","first-page":"11981204","DOI":"10.1016\/S0735-1097(03)00048-2","article-title":"Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin.","volume":"41","author":"Belhassen","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R15-28-20241201","doi-asserted-by":"crossref","first-page":"199205","DOI":"10.1124\/jpet.110.165787","article-title":"Terutroban, a thromboxaneprostaglandin endoperoxide receptor antagonist, increases survival in strokeprone rats by preventing systemic inflammation and endothelial dysfunction: comparison with aspirin and rosuvastatin.","volume":"334","author":"Gelosa","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"R16-28-20241201","doi-asserted-by":"crossref","first-page":"H762H768","DOI":"10.1152\/ajpheart.00880.2010","article-title":"Terutroban, a thromboxaneprostaglandin endoperoxide receptor antagonist, prevents hypertensive vascular hypertrophy and fibrosis.","volume":"300","author":"Gelosa","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R17-28-20241201","doi-asserted-by":"crossref","first-page":"110119","DOI":"10.2337\/diabetes.55.01.06.db05-0831","article-title":"The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein Edeficient mice.","volume":"55","author":"Xu","year":"2006","journal-title":"Diabetes"},{"key":"R18-28-20241201","doi-asserted-by":"crossref","first-page":"374381","DOI":"10.1016\/j.bcp.2009.04.022","article-title":"Thromboxane prostanoid receptor activation impairs endothelial nitric oxidedependent vasorelaxations: the role of Rho kinase.","volume":"78","author":"Liu","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"R19-28-20241201","doi-asserted-by":"crossref","first-page":"132138","DOI":"10.1002\/dmrr.1283","article-title":"Effects of terutroban, a thromboxaneprostaglandin endoperoxide receptor antagonist, on retinal vascularity in diabetic rats.","volume":"28","author":"De La Cruz","year":"2012","journal-title":"Diabetes Metab Res Rev"},{"key":"R20-28-20241201","first-page":"10331039","article-title":"PPARalpha activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats.","volume":"56","author":"RodriguezVilarrupla","year":"2012","journal-title":"J Hepatol"},{"key":"R21-28-20241201","doi-asserted-by":"crossref","first-page":"12451256","DOI":"10.1002\/hep.22758","article-title":"Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats.","volume":"49","author":"Mejias","year":"2009","journal-title":"Hepatology"},{"issue":"Suppl 3","key":"R22-28-20241201","first-page":"2027","article-title":"TP receptor antagonism: a new concept in atherothrombosis and stroke prevention.","volume":"27","author":"Chamorro","year":"2009","journal-title":"Cerebrovasc Dis"},{"key":"R23-28-20241201","doi-asserted-by":"crossref","first-page":"968974","DOI":"10.2337\/db06-1136","article-title":"Renal effects of S18886 (terutroban), a TP receptor antagonist, in an experimental model of type 2 diabetes.","volume":"56","author":"Sebekova","year":"2007","journal-title":"Diabetes"},{"key":"R24-28-20241201","doi-asserted-by":"crossref","first-page":"10581063","DOI":"10.1016\/S0895-7061(97)00276-8","article-title":"Losartan prevents thromboxane A2prostanoid (TP) receptor mediated increase in microvascular permeability in the rat.","volume":"10","author":"Valentin","year":"1997","journal-title":"Am J Hypertens"},{"key":"R25-28-20241201","doi-asserted-by":"crossref","first-page":"240246","DOI":"10.1016\/j.jhep.2012.09.010","article-title":"Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4cirrhotic rats.","volume":"58","author":"Guillaume","year":"2013","journal-title":"J Hepatol"},{"key":"R26-28-20241201","doi-asserted-by":"crossref","first-page":"926931","DOI":"10.1002\/hep.510280405","article-title":"Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats.","volume":"28","author":"Gupta","year":"1998","journal-title":"Hepatology"},{"key":"R27-28-20241201","first-page":"6263","article-title":"Simvastatin improves sinusoidal endothelial dysfunction in CCl4 cirrhotic rats.","volume":"42","author":"Abraldes","year":"2005","journal-title":"Journal of Hepatology"},{"key":"R28-28-20241201","first-page":"660665","article-title":"Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats.","volume":"54","author":"GarciaCaldero","year":"2010","journal-title":"J Hepatol"},{"key":"R29-28-20241201","first-page":"566573","article-title":"Largeconductance calciumactivated potassium channels modulate vascular tone in experimental cirrhosis.","volume":"28","author":"RodriguezVilarrupla","year":"2008","journal-title":"Liver Int"},{"key":"R30-28-20241201","doi-asserted-by":"crossref","first-page":"G45360","DOI":"10.1152\/ajpgi.00315.2002","article-title":"Role of Thromboxane A2 in Early BDLinduced Portal Hypertension.","volume":"284","author":"Yokoyama","year":"2003","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R32-28-20241201","doi-asserted-by":"crossref","first-page":"709719","DOI":"10.1053\/j.gastro.2006.12.041","article-title":"Nitroflurbiprofen, a nitric oxidereleasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.","volume":"132","author":"Laleman","year":"2007","journal-title":"Gastroenterology"},{"key":"R33-28-20241201","doi-asserted-by":"crossref","first-page":"430435","DOI":"10.1016\/0016-5085(85)90503-7","article-title":"Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver.","volume":"88","author":"Bruix","year":"1985","journal-title":"Gastroenterology"},{"key":"R34-28-20241201","first-page":"891900","article-title":"Cyclooxygenase1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites.","volume":"135","author":"LopezParra","year":"2002","journal-title":"Br J Pharmacol"},{"key":"R35-28-20241201","doi-asserted-by":"crossref","first-page":"215222","DOI":"10.1016\/0016-5085(79)90268-3","article-title":"Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease.","volume":"77","author":"Boyer","year":"1979","journal-title":"Gastroenterology"},{"key":"R36-28-20241201","doi-asserted-by":"crossref","first-page":"20132022","DOI":"10.1016\/S0140-6736(11)60600-4","article-title":"Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, doubleblind, parallelgroup trial.","volume":"377","author":"Bousser","year":"2011","journal-title":"Lancet"},{"key":"R37-28-20241201","doi-asserted-by":"crossref","first-page":"23692376","DOI":"10.1111\/j.1538-7836.2010.04020.x","article-title":"Thromboxane antagonism with terutroban in peripheral arterial disease: the TAIPAD study.","volume":"8","author":"Fiessinger","year":"2010","journal-title":"J Thromb Haemost"},{"key":"R38-28-20241201","doi-asserted-by":"crossref","first-page":"1712017128","DOI":"10.1074\/jbc.M109.012583","article-title":"Thromboxane A2 receptor activates a Rhoassociated kinaseLKB1PTEN pathway to attenuate endothelium insulin signaling.","volume":"284","author":"Song","year":"2009","journal-title":"J Biol Chem"},{"key":"R40-28-20241201","doi-asserted-by":"crossref","first-page":"12961305","DOI":"10.1136\/gut.2005.081059","article-title":"Intrahepatic upregulation of RhoA and Rhokinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis.","volume":"55","author":"Zhou","year":"2006","journal-title":"Gut"},{"key":"R41-28-20241201","doi-asserted-by":"crossref","first-page":"12201227","DOI":"10.1016\/j.jhep.2012.07.033","article-title":"HSCspecific inhibition of Rhokinase reduces portal pressure in cirrhotic rats without major systemic effects.","volume":"57","author":"Klein","year":"2012","journal-title":"J Hepatol"},{"key":"R42-28-20241201","doi-asserted-by":"crossref","first-page":"209218","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis.","volume":"115","author":"Bataller","year":"2005","journal-title":"J Clin Invest"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.26520","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201310000-00028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T14:08:43Z","timestamp":1733062123000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201310000-00028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.26520","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}